Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 2/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388208 | 0.80 | HPGD (0.73) | HPGDEPHX2TSHRCALM1FDPS | |
| SCHEMBL9972116 | 0.76 | HPGD (0.54) | HPGDEPHX2TSHRCALM1FDPS | |
| SCHEMBL10424306 | 0.76 | HPGD (0.54) | HPGDEPHX2TSHRCALM1FDPS | |
| SCHEMBL497159 | 0.76 | HPGD (0.60) | HPGDTSHRFDPSCYP2C19LAP3 | |
| SCHEMBL73500 | 0.76 | HPGD (0.54) | HPGDEPHX2TSHRCALM1FDPS | |
| SCHEMBL11300130 | 0.76 | HPGD (0.54) | HPGDEPHX2TSHRCALM1FDPS | |
| Benzylphosphonic Acid SCHEMBL44318 | 0.76 | HPGD (0.60) | HPGDTSHRLAP3ANPEP | |
| SCHEMBL8890450 | 0.76 | HPGD (0.54) | HPGDEPHX2TSHRCALM1FDPS | |
| SCHEMBL10424304 | 0.76 | HPGD (0.54) | HPGDEPHX2TSHRCALM1FDPS | |
| SCHEMBL2150764 | 0.76 | HPGD (0.54) | HPGDEPHX2TSHRCALM1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0567107-B1 | Quinoline and quinazoline derivatives for treating arthritis | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-11-21 | — | — | EP | claimed |
| EP-0608870-B1 | Quinoline or quinazoline derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-09-05 | — | — | EP | claimed |
| US-5948782-A | ANTIINFLAMMATORY AGENT; RHEUMATIC DISEASES | TAKEDA CHEMICAL (JP) | 1999-09-07 | — | — | US | claimed |
| US-5770602-A | REACTING QUIONOZOLINE OR QUINOLINE DERIVATIVES CONTAINING LEAVING GROUPS WITH NITROGEN CONTAINING UNSATURATED CYCLIC GROUP WHICH MAY BE SUBSTITUTED OR UNSUBSTITUTED; ANTIARTHRITIC AGENT | TAKEDA CHEMICAL INDUSTRIES (JP) | 1998-06-23 | — | — | US | claimed |
| EP-0608870-A1 | Quinoline or quinazoline derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-03 | — | — | EP | claimed |
| EP-0567107-A1 | Quinoline and quinazoline derivatives for treating arthritis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | claimed |
| EP-1838678-A1 | PROCESS FOR OBTAINING CIZOLIRTINE AND ITS ENANTIOMERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-03 | — | — | EP | disclosed |
| EP-1828175-A2 | PROCESS FOR OBTAINING ENANTIOMERS OF THIENYLAZOLYLALCOXYETHANAMINES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| US-7109349-B2 | Process for obtaining Cizolirtine and its enantiomers | LABORATORIOS DEL DR. ESTEVE, S/A (ES) | 2006-09-19 | — | — | US | disclosed |
| US-7078531-B2 | Process for obtaining enantiomers of thienylazolylalcoxyethanamines | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2006-07-18 | — | — | US | disclosed |
| WO-2006069766-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIZOLIRTINE | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006069767-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF THIENYLAZOLYLALCOXYETHANAMINES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142589-A1 | Process for obtaining enantiomers of Cizolirtine | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-29 | — | — | US | disclosed |
| US-4689333-A | ANTIULCER AGENTS, CASTRITIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-08-25 | — | — | US | disclosed |
| EP-0208452-A2 | Pyridine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-01-14 | — | — | EP | disclosed |
| US-4628098-A | Including Prevacid (TM) lansoprazole, 2-(3-methyl-4-(2,2,2-trifluoroethoxy)-5-methyl-pyrid-2 -yl)methylsulfinylbenzimidazole; proton pump inhibitors, antiulcer, antisecretory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-12-09 | — | — | US | disclosed |
| EP-0175464-A1 | Benzimidazole derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1986-03-26 | — | — | EP | disclosed |
| EP-0174726-A1 | Pyridine derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1986-03-19 | — | — | EP | disclosed |
| US-4451471-A | Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same | CIBA-GEIGY CORPORATION (US) | 1984-05-29 | — | — | US | disclosed |
| EP-0061425-A2 | Thiazole derivatives, processes for their preparation, medicaments containing them and their use | CIBA-GEIGY AG (CH) | 1982-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142589-A1 | Process for obtaining enantiomers of Cizolirtine | MAP2K5, MAP2K4, MAP2K1 | HPGD 2240/4885EPHX2 1535/4885TSHR 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.